晚期黑色素瘤BRAF/MEK抑制剂治疗后的长期结局与持续毒性
这项回顾性多中心队列研究纳入四个国家八家机构中BRAF/MEK抑制剂治疗后无进展生存超过4年的146例晚期黑色素瘤患者,中位随访7.8年时112例(76.7%)仍无进展、131例(89.7%)存活,因非进展原因停药者中13例(19%)进展,长期毒性不常见且为低级别。
要点
- 146例4年PFS患者中位随访7.8年,76.7%仍无进展,89.7%存活。
- 因毒性或偏好等非进展原因停药者68例中13例(19%)进展。
- 末次随访时13例(8.9%)有持续毒性,均为低级别,心脏不良事件均已缓解。
核心结论
- 超过75%的BRAF/MEK抑制剂治疗后4年无进展生存患者在中位近8年随访后仍保持持续持久的抗肿瘤应答,因非进展原因停药者结果相似。
- 长期毒性不常见且为低级别,这些发现突出显示了从BRAF/MEK抑制剂获得持久获益患者的良好结局。
研究设计与样本
- 回顾性多中心队列研究,纳入四个国家八家机构中BRAF/MEK抑制剂治疗后无进展生存超过4年的晚期黑色素瘤患者146例。
- 评估患者的应答、进展和不良事件。
主要发现
- 146例患者中,从治疗开始中位随访7.8年时112例(76.7%)仍无进展,131例(89.7%)存活。
- 进展者34例中21例(62%)进展时仍在治疗。
- 因毒性、偏好等非进展原因停药者68例(中位治疗持续时间49个月),其中13例(19%)进展,从停药至进展中位15.3个月。
- 针对单器官进展的手术或放疗使22例中11例(50%)获得持久获益;后续系统治疗包括免疫治疗(24%应答)和BRAF/MEK再挑战(56%应答)。
- 末次随访时13例(8.9%)有持续毒性,其中10例(77%)仍在积极治疗;所有心脏不良事件均已缓解(n=9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent studies have shown that approximately 20% of patients have 4-5 year progression free survival (PFS) on BRAF/MEK inhibitors. The long-term safety and efficacy in these patients with more durable responses have not been studied. METHODS: This retrospective multicenter cohort study assessed response, progression, and adverse events in patients from eight institutions in four countries with >4-year PFS following BRAF/MEK inhibitors. RESULTS: Among 146 patients, 112 (76.7%) remained progression-free at median follow-up of 7.8 years from treatment start; 131 (89.7%) were alive. Among progressors (n = 34), 21 (62%) were on treatment at progression. Among those who discontinued treatment for reasons other than progression (toxicity, preference, etc.) (n = 68, with median 49 months treatment duration), 13 (19%) progressed (median 15.3 months from treatment cessation to progression). Surgery or radiation for single-organ progression resulted in durable benefit in 11 of 22 patients (50%). Subsequent systemic therapy included immune therapy (24% responded) and BRAF/MEK rechallenge (56% responded). Thirteen (8.9%) patients had ongoing toxicities at last follow-up, 10 (77%) of which remained on active treatment; all cardiac adverse events had resolved (n = 9). Twenty-four (16.4%) patients developed any new primary cancer, and 28 (19%) patients experienced other major health events. CONCLUSIONS: Over 75% of patients with 4-year PFS from BRAF/MEK inhibitors had continued durable antitumor responses after nearly 8-year median follow-up, with similar results in patients who discontinued therapy for reasons other than progression. Long-term toxicities were uncommon and low-grade. These findings highlight the often-favourable outcomes in patients with extended benefit from BRAF/MEK inhibitors.
引用
- Goodman RS, Di Guardo L, Maurichi A, et al. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. Eur J Cancer. 2023. PMID: 37827067. doi:10.1016/j.ejca.2023.113354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。